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Abstract
Background: Fleas are the most common ectoparasite infesting dogs globally and cause direct discomfort, induce
allergic reactions, and transmit pathogenic agents. Rapid speed of kill is an important characteristic for a parasiticide
in order to alleviate the direct deleterious effects of fleas, reduce the impact of allergic responses, and break the
flea life cycle. In this study, the speed of kill of a novel, orally administered isoxazoline parasiticide, sarolaner
(Simparica™), against fleas on dogs was evaluated and compared with fluralaner (Bravecto®) over a 3-month period.
Methods: Based on pretreatment flea counts, 24 dogs were randomly allocated to treatment with oral sarolaner at
the label rate (2 to 4 mg/kg), once a month for 3 months, or oral fluralaner (25 to 50 mg/kg), once per label
directions, or placebo. Dogs were combed and live fleas counted at 8, 12, and 24 h after treatment and subsequent
re-infestations on Days 14, 29, 44, 59, 74 and 90. Efficacy was determined at each time point relative to counts for
placebo dogs.
Results: There were no adverse reactions to treatment. Three monthly doses of sarolaner provided ≥97.6 % efficacy
(based on arithmetic means) within 8 h of treatment or subsequent weekly re-infestations of fleas for 3 months. By
12 h, fleas were eradicated from all dogs (100 % efficacy). Significantly greater numbers of live fleas were recovered
from fluralaner-treated dogs at 8 h on Days 74 and 90 (P≤ 0.0043) when efficacy (based on arithmetic means) was
only 80.7 and 72.6 %, respectively.
Conclusions: In this controlled laboratory evaluation, sarolaner had a significantly faster speed of kill against fleas
than fluralaner at the end of its claimed treatment period. The rapid and consistent kill of fleas within 8 to 12 h
after monthly oral doses of sarolaner indicates that this treatment will provide rapid and highly effective control of
flea infestations, and suggests that it will provide relief for dogs suffering from flea allergy dermatitis, and should
reduce the risk of flea-borne pathogen transmission.
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Background
The cat flea, Ctenocephalides felis felis, is the most com-
mon ectoparasite of dogs and cats worldwide [1, 2]. In
addition to direct irritation and other deleterious effects of
their blood-feeding, they cause flea allergic dermatitis
(FAD), which is the major dermatologic disease of dogs
[3]. Fleas also serve as the vector of various bacterial
pathogens and are the intermediate host for filarioid and
cestode parasites [4–9].
Flea infestations of pets and the home are a common
occurrence and their control and elimination is often a
challenge [1]. Fleas feed almost immediately on attaining
a host [10], and direct irritation and allergic reactions
are dependent upon the frequency and duration of
feeding [11]. Also, the longer that a host is exposed to
feeding fleas, the greater the chance of the transmission
of flea-borne pathogens. Therefore, the rapid kill and
removal of live fleas from the host is essential to ameli-
orate the direct effects of flea infestations and the associ-
ated adverse clinical conditions and diseases they can
cause. Highly effective topical and systemic parasiticides
have allowed the primary means of flea control to be
through the direct treatment of the pet. These have largely
eliminated the need to treat the environment, and their
wide spread use as host-targeted therapies has reduced
the severity and prevalence of FAD [2]. Recently, a new
class of compounds, the isoxazolines, have shown excel-
lent efficacy against both fleas and ticks for a month or
longer following a single orally administered dose [12, 13].
Sarolaner (Simparica™, Zoetis) is a new isoxazoline
effective against fleas and ticks for one month following
a single dose. A laboratory study was conducted to
compare the efficacy and speed of kill of three monthly
doses of sarolaner (Simparica™) with a single oral dose
of fluralaner (Bravecto®, Merck) against an existing flea
(C. felis) infestation and subsequent re-infestations over a
period of 3 months.
Methods
Ethical approval
The study was a masked, negative controlled, randomized,
laboratory efficacy design conducted in the Republic of
South Africa. Procedures were in accordance with the
World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the efficacy
of parasiticides for the treatment, prevention and control of
flea and tick infestation on dogs and cats [14] and complied
with the principles of Good Clinical Practices [15]. The
protocol was reviewed and approved by the local Institu-
tional Animal Care and Use Committee. Masking of the
study was assured through the separation of functions. All
personnel conducting observations or animal care or
performing infestations and counts were masked to treat-
ment allocation.
Animals
Twenty-four, male and female, purpose-bred dogs
(one Beagle and 23 mongrels) ranging in age from 12
to 76 months, and weighing from 9.6 to 29.2 kg were
used in the study. Each dog was individually identi-
fied by electronic transponder. All dogs had under-
gone an adequate wash-out period to ensure that no
residual ectoparasiticide efficacy remained from any
previously administered compound. The dogs were
acclimatized to study conditions for a minimum of 14
days before the treatment on Day 0. Dogs were indi-
vidually housed in indoor runs such that no physical
contact was possible between them. Dogs were fed an
appropriate maintenance ration of a commercial dry
canine feed, and water was available ad libitum. All
dogs were given a physical examination to evaluate
general health and suitability for inclusion into the
study. General health observations were performed at
least once daily from the start of the acclimation
period to the end of the study.
Design
The study followed a randomized complete block
design. Dogs were ranked according to decreasing
pretreatment flea counts into blocks of three and
within each block a dog was randomly allocated to
treatment with either placebo or sarolaner on Days 0,
30 and 60, or to treatment with fluralaner on Day 0
followed by placebo on Days 30 and 60 (to maintain
masking). There were eight dogs per treatment group.
Dogs were infested with fleas one day prior to the initial
treatment and then at approximately 14-day intervals
(Days 14, 29, 44, 59, 74 and 90) for 3 months. Flea counts
were conducted at 8, 12, and 24 h after the initial treat-
ment and each subsequent re-infestation. The 24-hour flea
counts on Days 30 and 60 were conducted prior to treat-
ment administration.
Treatment
Day -1, 29, and 59 bodyweights were used to determine
the appropriate doses to be administered on Days 0, 30,
and 60, respectively. On each treatment day, dogs
received either a placebo tablet, the appropriate
strength Simparica™ chewable tablet to provide sarola-
ner at the recommended label dose of 2 mg/kg
(range: 2 to 4 mg/kg), or Bravecto® only on Day 0,
per label directions (fluralaner at 25 to 50 mg/kg). On
days 30 and 60, dogs in the fluralaner group were adminis-
tered placebo. All doses were administered by hand pilling
to ensure accurate and complete dosing. Each dog was
observed for several minutes after dosing for evidence that
the dose was swallowed, and for general health at 1, 4, and
24 h after treatment administration. In order to comply
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with Bravecto® label requirements, all dogs were offered
their regular ration within 30 min of treatment.
Flea infestation and assessment
The C. felis used in the study were from a locally
maintained laboratory colony of European origin. The
colony was initiated in 2010 with fleas from Germany.
Additional fleas obtained from Ireland were intro-
duced into the colony in 2012 (approximately two
years prior to the study). Flea infestations were per-
formed on Days -7 (host suitability and allocation),
-1, 14, 29, 44, 59, 74, and 90. At each infestation a
pre-counted aliquot of 100 (±5) adult, unfed C. felis
were directly applied to the animal which was gently
restrained for a few minutes to allow the fleas to
penetrate and disperse into the hair coat. Each dog
was examined and combed to remove and count fleas
at 24 h after the initial host suitability infestation,
and at 8, 12, and 24 (±1) hours after treatment and
each subsequent weekly re-infestation. Fleas were re-
placed on the dogs immediately after each 8 and 12 h
evaluation, and discarded after the 24 h counts.
Flea counts were performed by personnel trained in
the standard procedures in use at the test facility.
Commercial fine-toothed flea combs were used. Dogs
were combed using repeated strokes initially while
standing, starting from the head, then proceeding
caudally along the dorsum. The dog was then placed
on each side and then on its back for combing of the
sides and ventral surfaces. After a few combing
strokes were completed, the comb was examined and
hair and fleas were removed from the comb and all
live fleas were counted. Dogs were repeatedly combed
for a minimum of 10 min; if any fleas were recovered
in the last minute, combing was continued in one-
minute increments until no fleas were detected.
Statistical analysis
The individual dog was the experimental unit and the
primary endpoint was the live flea count. Data for
post-treatment flea counts were summarized with
arithmetic (AM) and geometric (GM) means by treat-
ment group and timepoint. Flea counts were trans-
formed (loge(count + 1)) prior to analysis to stabilize
the variance and normalize the data. Using the PROC
MIXED procedure (SAS 9.2, Cary NC), transformed
counts were analyzed using a mixed linear model.
The fixed effects were treatment, timepoint and the
interaction between timepoint and treatment by time-
point. The random effects included room, block
within room, block by treatment interaction, and
error. Testing was two-sided at the significance level
α = 0.05.
The assessment of efficacy was based on the percent
reduction in the AM and GM live flea counts relative to
placebo calculated using Abbott’s formula:
% reduction
¼ 100  mean count placeboð Þ–mean count treatedð Þ
mean count placeboð Þ
Results
There were no treatment-related adverse events during
the study. Placebo-treated dogs maintained good flea in-
festations throughout the study and these counts were
maintained even following the combing and re-infestation
procedures at 8 and 12 h (Tables 1, 2 and 3).
At the 8-hour time point, both treatments resulted in
significantly lower flea counts than placebo-treated dogs
(P < 0.0001) throughout the study (Table 1). Treatment
with sarolaner also resulted in significantly lower flea
counts than fluralaner at 8 h on Days 74 and 90
(P ≤ 0.0043). The sarolaner treatment provided consist-
ent, high efficacy at 8 h (≥98.6 %, ≥97.6 % GM, AM) for
the entire study. Efficacy for fluralaner declined to 90.0 %
and 92.7 % (GM), and to 80.7 % and 72.6 % (AM) on Days
74 and 90, respectively (Table 1). Over 50 live fleas were
found on a fluralaner-treated dog on Days 74 and 90,
while a maximum of only eight live fleas were collected
from a single sarolaner-treated dog on Day 29. Sarolaner-
treated dogs were free of fleas on Day 74 and only a single
live flea was recovered on Day 90 (efficacy of 99.8 %, AM
and GM).
At the 12-hour timepoint, both treatments resulted in
significantly lower flea counts than placebo-treated dogs
(P < 0.0001) throughout the study (Table 2). At 12 h, flea
counts were not significantly different between sarola-
ner- and fluralaner-treated dogs on any day (P ≥ 0.0630).
Efficacy was consistently high for sarolaner with all dogs
being free of fleas within 12 h after treatment and re-
infestations through Day 90. For fluralaner, 100 %
efficacy was achieved within 12 h after treatment and
reinfestations up to Day 44. However, efficacy in the
final month of the 3-month treatment period (Fig. 1)
declined to 98.9 % and 98.4 % (GM) and 96.1 % and
95.5 % (AM) on Days 74 and 90, respectively
(Table 2). As many as 17 live fleas were found on
fluralaner-treated dogs at the 12-hour counts on Days
74 and 90.
At the 24-hour time point, both treatments resulted in
significantly lower flea counts than placebo-treated dogs
(P < 0.0001) throughout the study (Table 3). Both
products provided ≥99.8 % reduction in mean live flea
counts through Day 90 with 100 % efficacy at most
evaluations (Table 3); there was no difference between
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Table 1 Mean live flea counts and efficacy relative to placebo at 8 hours after initial treatment and post-treatment re-infestations for
dogs treated with three monthly oral doses of sarolaner or a single oral dose of fluralaner
Treatment Day of initial treatment or re-infestation1
0 14 29 44 59 74 90
Placebo Range 44–94 71–86 39–96 48–93 35–91 58–93 30–71
A. mean 75.0 75.5 73.1 70.8 72.5 72.4 56.1
G. mean2 73.3a 75.4a 70.2a 69.0a 69.5a 71.4a 54.5a
Sarolaner Range 0–0 0–0 0–8 0–0 0–2 0–0 0–1
A. mean 0.0 0.0 1.8 0.0 0.5 0.0 0.1
Efficacy (%) 100 100 97.6 100 99.3 100 99.8
G. mean2 0.0b 0.0b 1.0b 0.0b 0.4b 0.0c 0.1c
Efficacy (%) 100 100 98.6 100 99.5 100 99.8
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Fluralaner Range 0–0 0–1 0–4 0–0 0–19 0–54 0–63
A. mean 0.0 0.1 0.6 0.0 2.6 14.0 15.4
Efficacy (%) 100 99.8 99.1 100 96.4 80.7 72.6
G. mean2 0.0b 0.1b 0.3b 0.0b 0.7b 7.1b 4.0b
Efficacy (%) 100 99.9 99.5 100 99.0 90.0 92.7
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 1.000 0.3311 0.2334 1.0000 0.4991 <0.0001 0.0043
1Sarolaner administered on Days 0, 30, 60; fluralaner on Day 0 only
2Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Table 2 Mean live flea counts and efficacy relative to placebo at 12 hours after initial treatment and post-treatment re-infestations
for dogs treated with three monthly oral doses of sarolaner or a single oral dose of fluralaner
Treatment Day of treatment or re-infestation1
0 14 29 44 59 74 90
Placebo Range 39–90 54–74 30–91 45–87 37–81 45–82 21–71
A. mean 68.0 65.3 63.8 65.6 66.9 64.1 50.5
G. mean2 66.1a 64.9a 60.2a 63.5a 65.2a 63.0a 47.4a
Sarolaner Range 0–0 0–0 0–0 0–0 0–0 0–0 0–0
A. mean 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Efficacy (%) 100 100 100 100 100 100 100
G. mean2 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b
Efficacy (%) 100 100 100 100 100 100 100
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Fluralaner Range 0–0 0–0 0–0 0–0 0–1 0–17 0–15
A. mean 0.0 0.0 0.0 0.0 0.1 2.5 2.3
Efficacy (%) 100 100 100 100 99.8 96.1 95.5
G. mean2 0.0b 0.0b 0.0b 0.0b 0.1b 0.7b 0.8b
Efficacy (%) 100 100 100 100 99.9 98.9 98.4
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 1.000 1.000 1.000 1.0000 0.4040 0.1128 0.0630
1Sarolaner administered on Days 0, 30, 60; fluralaner on Day 0 only
2Geometric means within columns with the same superscript are not significantly different (P > 0.05)
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the counts for the two products on any assessment
day (P ≥ 0.4444).
Discussion
The initial speed of kill of a parasiticide is important to
provide the pet with rapid relief from the existing
infestation, and rapid killing of new flea infestations
consistently throughout the treatment period is critical
to assist in the management of flea allergic dermatitis, to
eliminate fleas before they can reproduce, and to
decrease the likelihood of vector-borne pathogen trans-
mission. Three monthly oral doses of sarolaner at the
Table 3 Mean live flea counts and efficacy relative to placebo at 24 hours after initial treatment and post-treatment re-infestations
for dogs treated with three monthly oral doses of sarolaner or a single oral dose of fluralaner
Treatment Day of treatment or re-infestation1
0 14 29 44 59 74 90
Placebo Range 33–91 43–69 29–89 41–73 38–77 38–75 12–74
A. mean 64.6 56.8 56.1 55.8 61.9 55.6 46.9
G. mean2 62.3a 56.0a 53.4a 54.0a 60.7a 54.4a 41.5a
Sarolaner Range 0–1 0–0 0–0 0–0 0–0 0–0 0–0
A. mean 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Efficacy (%) 99.8 100 100 100 100 100 100
G. mean2 0.1b 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b
Efficacy (%) 99.9 100 100 100 100 100 100
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Fluralaner Range 0–0 0–0 0–0 0–0 0–0 0–0 0–0
A. mean 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Efficacy (%) 100 100 100 100 100 100 100
G. mean2 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b 0.0b
Efficacy (%) 100 100 100 100 100 100 100
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-value vs. sarolaner 0.4444 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
1Sarolaner administered on Days 0, 30, 60; fluralaner on Day 0 only
2Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 8 and 12 hours after initial treatment and post-treatment re-infestations
of fleas for dogs treated with three monthly oral doses of sarolaner or a single oral dose of fluralaner
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label rate of 2 to 4 mg/kg resulted in the rapid reduction
of an existing flea infestation after the first dose, and the
rapid and consistent kill of newly infested fleas for 90
days. Treatment with sarolaner resulted in effective flea
control of greater than 97.6 % (AM) within 8 h after
treatment and re-infestations for 90 days, and eliminated
fleas from all dogs within 12 h over the entire 90 days.
This rapid and consistent efficacy will disrupt the flea life
cycle by killing adult fleas before they can lay eggs, thus
reducing the environmental infestation level [16, 17].
The efficacy provided by fluralaner in the last half
month of its 3-month claimed treatment period was
lower and it required up to 24 h to eradicate fleas fol-
lowing re-infestations on Days 59, 74, and 90. Signifi-
cantly more live fleas were found on fluralaner-treated
dogs (up to 63 fleas/dog) than on sarolaner-treated dogs
(a single flea on one dog) on Days 74 and 90 (P ≤
0.0043) at the 8-hour time point. This pattern reflects
the treatment intervals for the two products; sarolaner
as a monthly administered tablet, and fluralaner as single
dose to provide efficacy for up to 3 months. The
relatively high dose required to achieve the persistent
efficacy of fluralaner results in rapid speed of kill of fleas
in the initial part of the treatment period, but this
declines significantly relative to the efficacy of monthly
sarolaner towards the end of the 3-month treatment
period, while sarolaner maintains rapid and consistent
speed of kill. To ensure that veterinarians and owners
can be confident of protection against fleas, consistent
and rapid speed of kill is essential for the entire treat-
ment period. The decline in speed of kill for fluralaner
in the last few weeks of the 3-month treatment period
results in a possible gap in protection that could increase
the risk of FAD or the transmission of flea-borne patho-
gens relative to a monthly treatment such as sarolaner,
which provides consistent speed of kill for the entire
treatment period.
The rapid and consistent speed of kill of fleas over a
period of 30 days makes sarolaner an excellent option
for flea control that will probably reduce the direct irri-
tation caused by flea infestation, will assist in preventing
the clinical signs of FAD, and should reduce the risk of
flea-borne infections and diseases.
Conclusions
Three monthly doses of sarolaner provided rapid and con-
sistent control of existing infestations and re-infestations
of fleas from 8 h onwards. The speed of kill of fluralaner
however declined significantly relative to that of sarolaner
during the last half month, with significantly more fleas
found on fluralaner-treated dogs at 8 h after infestations
on Days 74 and 90. This superior speed of kill of sarolaner
at the end of the 3 months, combined with its consistent
efficacy, indicates that monthly treatment with sarolaner
chewable tablets (Simparica™) may provide more consist-
ent protection against fleas and will probably reduce the
deleterious effects of flea infestation, prevent the clinical
signs of FAD, and reduce the risk of flea-borne diseases.
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